Earnings call transcript: Haemonetics beats Q1 2026 estimates, stock slips premarket

Haemonetics (HAE) beat fiscal Q1 estimates with adjusted EPS of $1.14 vs $1.09 (up 4.6%) and revenue of $339M vs $328.9M (up 3.1%), but shares fell 1.91% in premarket to about $82, reflecting margin pressure and a cautious read on the outlook. Management raised full-year fiscal 2027 revenue guidance to 5%–8% reported growth and 4%–7% organic growth, while maintaining its 50–100 bps adjusted operating margin expansion target. Gross margin was 60.4% (down 40 bps YoY) and adjusted operating margin was 23.4% (down 70 bps), even as free cash flow was unusually strong (75% of adjusted net income conversion). Cash strength continued with operating cash flow of $52M (~3x prior year) and net leverage around 2.69x EBITDA, supporting ongoing debt reduction and continued buyback capacity.

Analysis

The market is treating this like a quality-multiple story, not a one-quarter beat: the real driver is that HAE is converting an installed base upgrade cycle into recurring, low-capex revenue with better retention. That matters because firmware/software adoption tends to front-run operating leverage — once rollout crosses a threshold, incremental revenue can outpace incremental cost, and competitors in plasma collection and closure are forced into either price concessions or slower product cycles. The second-order winner is HAE’s balance sheet: stronger cash conversion and buyback/deleveraging optionality reduce the chance of multiple compression even if growth normalizes.

The near-term risk is that expectations are now high enough that any pause in sequential margin expansion or launch cadence will punish the stock harder than the headline beat deserves. Management’s own guidance is intentionally de-risked, which creates upside if adoption or international label timing accelerates, but also means the next catalyst is less about Q1 and more about whether Q2/Q3 show real gross-margin slope improvement. Watch for failure of cash conversion to stay elevated, or for cost inflation/freight/oil to consume the tariff benefit; that would be the cleanest falsifier.

Contrarian view: consensus is focused on the P/E and the slight margin downtick, but may be underweighting how much of this business is becoming usage-based rather than purely capital-cycle driven. If Persona-plus-type rollouts and closure label expansion keep compounding, HAE can sustain a premium multiple longer than skeptics expect. The flip side is that at this valuation, no one is paying for only mid-single-digit growth; investors need evidence of re-acceleration, not just stability.

Key Decisions for Investors

• Tactically buy HAE on a pullback into the low-80s with a 1-3 month target of the mid-90s fair-value area; thesis breaks if the next quarter fails to show sequential gross-margin improvement.
• Use a 3-6 month HAE call spread rather than outright stock if seeking upside exposure; this caps theta bleed while preserving participation in a launch-driven rerating.
• Do not short HAE outright here unless Q2 gross margin or FCF conversion misses guidance; the balance-sheet de-risking and buyback capacity create a bad risk/reward for a fresh short.
• For relative value, pair long HAE against a broader medtech basket ETF proxy such as IHI on weakness; HAE has more idiosyncratic upgrade-driven upside, while the basket is more exposed to multiple compression.